{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:46:10Z","timestamp":1786995970047,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.prro.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T14:13:54Z","timestamp":1721052834000},"page":"74-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1405-4897","authenticated-orcid":false,"given":"Andrew B.","family":"Barbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituraj","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Kutuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Jui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Fekrmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Skalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohann J.M.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Dal Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Della","family":"Biancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin S.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2024.06.012_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): A non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0003","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network: Kidney Cancer. (Version 2.2024).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed April 22, 2024."},{"key":"10.1016\/j.prro.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: The 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized renal cancer: Evaluation, management, and follow-up: AUA guideline: Part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0006","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.clgc.2018.07.024","article-title":"Imaging in suspected renal-cell carcinoma: Systematic review","volume":"17","author":"Vogel","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2024.06.012_bib0007","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.ijrobp.2023.06.402","article-title":"Final results from a prospective randomized pilot trial of stereotactic body radiation therapy vs. radiofrequency ablation for the management of small renal masses (RADSTER)","volume":"117","author":"Swaminath","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0008","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: A systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0009","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.3390\/cancers15143672","article-title":"The judicious use of stereotactic ablative radiotherapy in the primary management of localized renal cell carcinoma","volume":"15","author":"Barbour","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2024.06.012_bib0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0011","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: A systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.prro.2024.06.012_bib0012","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0013","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0014","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000329","article-title":"Stereotactic ablative radiotherapy (SABR) for large renal tumors: A retrospective case series evaluating clinical outcomes, toxicity, and technical considerations","volume":"41","author":"Correa","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-018-0992-3","article-title":"A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma","volume":"13","author":"Correa","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0016","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2024.06.012_bib0018","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0019","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0020","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.3390\/cancers14205069","article-title":"Stereotactic body radiotherapy for renal cell carcinoma in patients with von Hippel-Lindau disease-results of a prospective trial","volume":"14","author":"Kirste","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2024.06.012_bib0021","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.prro.2022.06.012","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell cancer: 24-month results of the RSR1 phase 1 dose escalation study","volume":"13","author":"Lapierre","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0022","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0023","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ijrobp.2023.12.005","article-title":"Evaluation of volumetric response assessment from stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC)","volume":"119","author":"Schep","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors","volume":"206","author":"Sun","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.prro.2024.06.012_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/1754-9485.12590","article-title":"Utility of 68Ga prostate specific membrane antigen \u2013 positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma","volume":"61","author":"Siva","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202387","article-title":"Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma","volume":"13","author":"Reynolds","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.prro.2024.06.012_bib0027","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3390\/jcm11071829","article-title":"PSMA PET\/CT in renal cell carcinoma: An overview of current literature","volume":"11","author":"Muselaers","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.prro.2024.06.012_bib0028","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"18FPSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: Preliminary results","volume":"48","author":"Mittlmeier","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2024.06.012_bib0029","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eururo.2023.03.025","article-title":"Stereotactic radiotherapy for renal cell carcinoma: The fallacy of (false) positive post-treatment biopsy?","volume":"84","author":"Correa","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0030","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0031","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000000111","article-title":"Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: A multicenter analysis from the IROCK","volume":"201","author":"Correa","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0032","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0033","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clon.2022.06.007","article-title":"Stereotactic body radiotherapy for renal cell carcinoma: oncological and renal function outcomes","volume":"35","author":"Glicksman","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2024.06.012_bib0034","article-title":"DMSA-SPECT: A novel approach to nephron sparing SBRT for renal cell carcinoma","volume":"6","author":"Chevli","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fonc.2016.00201","article-title":"The place of FDG PET\/CT in renal cell carcinoma: Value and limitations","volume":"6","author":"Liu","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmp.2021.07.020","article-title":"Reducing the impact on renal function of kidney SABR through management of respiratory motion","volume":"89","author":"Gaudreault","year":"2021","journal-title":"Phys Med"},{"key":"10.1016\/j.prro.2024.06.012_bib0037","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euo.2023.07.002","article-title":"Stereotactic magnetic resonance-guided adaptive radiation therapy for localized kidney cancer: Early outcomes from a prospective phase 1 trial and supplemental cohort","volume":"7","author":"Yim","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0038","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/cancers12102763","article-title":"The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer","volume":"12","author":"Tetar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2024.06.012_bib0039","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ucl.2023.01.007","article-title":"Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus","volume":"50","author":"Dason","year":"2023","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.prro.2024.06.012_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2004.04897.x","article-title":"The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus","volume":"94","author":"Blute","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2024.06.012_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.12.018","article-title":"Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus","volume":"40","author":"Freifeld","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0043","doi-asserted-by":"crossref","first-page":"10283","DOI":"10.3390\/curroncol30120749","article-title":"Incorporating stereotactic ablative radiotherapy into the multidisciplinary management of renal cell carcinoma","volume":"30","author":"Raj","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0044","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.012_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12894-024-01405-y","article-title":"Neoadjuvant stereotactic ablative body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumor thrombus: A prospective pilot study","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0046","article-title":"Survival after combining stereotactic body radiation therapy and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0047","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: Is there still a role for cytoreductive nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0048","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2018.09.016","article-title":"Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: An individualized approach to metastatic renal cell carcinoma","volume":"75","author":"Bhindi","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0049","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-naive oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0050","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: A single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.012_bib0051","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course Pembrolizumab for oligometastatic renal cell carcinoma\u2014the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.06.012_bib0052","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2022.10.004","article-title":"Real-world practice patterns and safety of concurrent radiotherapy and cabozantinib in metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium","volume":"6","author":"Loo Gan","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:20:30Z","timestamp":1736292030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850024001565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1879850024001565"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.012","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}